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An 18-year-old woman with a 2-year history of hypertension and headache was diagnosed with nora-
drenalin-secreting bilateral adrenal pheochromocytomas with paragangliomas in the background of 
von Hippel-Lindau disease with family histories and a missense mutation,  712C to T (Arg167Trp) in the 
VHL gene.  She had optic disc hemangioma in the left eye which gradually enlarged and caused serous 
retinal detachment on the macula in one year.  Low-dose external beam radiation (20 Gy) was adminis-
tered to the left eye using a lens-sparing single lateral technique.  She underwent craniotomy for cere-
bellar hemangioblastoma at the age of 22 years and total pancreatectomy for multiple neuroendocrine 
tumors at the age of 24 years.  In the 6-year follow-up period after the radiotherapy,  the optic disc 
hemangioma gradually reduced in size and its activity remained low,  allowing good central vision to 
be maintained.  External beam radiation is recommended as a treatment option for the initial therapy 
for optic disc hemangioma.
Key words: retinal (papillary,  optic disc) hemangioma,  von Hippel-Lindau disease,  pheochromocytoma,  pan-
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on Hippel-Lindau disease is an autosomal domi-
nant disease caused by mutations in the VHL 
gene,  a tumor suppressor gene [1-4].  The main 
manifestations,  described initially,  are retinal heman-
gioma and central nervous system hemangioma,  the 
latter of which is frequently cerebellar or spinal cord 
hemangioblastoma.  Later,  the syndrome has been 
known to be complicated with other neoplasms,  adre-
nal pheochromocytoma,  paraganglioma,  renal cell 
carcinoma,  islet cell tumors,  pancreatic cysts and 
neuroendocrine tumors,  epididymal cysts or cystade-
noma,  and endolymphatic sac tumor of the inner ear 
[1,  2].
　 Retinal hemangioma has posed therapeutic prob-
lems for ophthalmologists for almost a century [5,  6].  
External beam radiation was the ﬁrst method of treat-
ment introduced for retinal hemangioma [1],  but it 
has not been enthusiastically pursued recently,  and is 
positioned as a salvage therapy to be used only when 
other modalities of treatment have failed [7].  The 
other modalities are cryotherapy,  direct laser photo-
coagulation,  plaque radiotherapy,  transpupillary 
thermotherapy,  photodynamic therapy,  and intravit-
real injection of anti-vascular endothelial growth fac-
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tor (VEGF) antibody drugs [8-12].  The location of 
hemangioma in the retina is an important factor in 
determining the treatment options [5,  6]: retinal 
hemangioma in the midperipheral to peripheral retina 
can be treated by direct ablation such as laser photo-
coagulation and cryotherapy [8].  In contrast,  optic 
disc (papillary) hemangioma presents therapeutic chal-
lenges to ophthalmologists [10].  In this study,  we 
present the long-term stabilizing eﬀect of external 
beam radiation to optic disc hemangioma in a patient 
with von Hippel-Lindau disease who underwent sur-
geries for bilateral adrenal pheochromocytomas,  cer-
ebellar hemangioblastoma,  and pancreatic neuroendo-
crine tumors.
Case Report
　 At 9 months of the age,  the patient was ﬁrst 
brought to the Department of Ophthalmology,  
Okayama University Hospital,  due to occasional 
esotropia noted from birth.  Cycloplegic refraction 
with atropine revealed hyperopia with ＋5.0 diopters 
in both eyes,  and the patient began wearing glasses to 
achieve orthophoria upon the diagnosis of accommoda-
tive esotropia.  At that time,  a fundus examination 
under mydriasis by atropine revealed no abnormali-
ties.  She was followed afterwards for several years to 
develop good visual acuity in both eyes and good ste-
reoacuity.
　 The patientʼs paternal grandmother was alive with 
a history of adrenal pheochromocytoma,  breast can-
cer,  and carcinoids,  the patientʼs father died at the 
age of 34 years of pancreatic cancer associated with 
bilateral adrenal pheochromocytomas,  paragan-
gliomas,  and carcinoids,  and a younger brother had 
surgeries for adrenal pheochromocytomas,  paragan-
gliomas,  and insulinoma.
　 The patient began to experience headache and 
palpitation from the age of 16 years.  At 18 years old,  
she was found to have bilateral adrenal tumors (Fig. 
1A,  B) as well as multiple pancreatic masses (7 in the 
pancreatic head and one in the tail) by magnetic reso-
nance imaging.  The serum noradrenalin was elevated 
to 6.85ng/mL (normal: 0.10-0.50ng/mL) while the 
serum adrenalin and dopamine were in the normal 
ranges.  Insulinoma was ruled out by insulin secretion 
tests,  and thus non-functioning neuroendocrine tumors 
were suspected for the pancreatic tumors.  She under-
went total extirpation of the bilateral adrenal tumors,  
together with extirpation of 2 paraaortic small masses,  
which were proven to be pheochromocytomas and 
paragangliomas,  respectively,  by pathological exami-
nations (Fig. 2A).  She was given oral hydrocortisone 
at a dose of 25mg daily.  Partial or total pancreatic 
resection was not chosen by the patient and her 
mother at the same time as the bilateral adrenal 
tumors extirpation because they considered it to be too 
much intervention.  Genomic analysis of peripheral 
leukocytes revealed a heterozygous missense mutation,  
712C to T (Arg167Trp),  in the VHL gene.
　 At that time at the age of 18 years,  she was found 
to have optic disc hemangioma in the left eye (Fig. 
3A).  The patientʼs best-corrected visual acuity was 1.5 
with －1.0 diopter correction in the right eye and 1.0 
with －1.0 diopter correction in the left eye.  The 
right eye was normal.  One year later,  at the age of 19 
years,  she underwent 20 Gy radiation (in 10 fractions 
using the lens-sparing single lateral technique) to the 
optic disc hemangioma,  since the serous retinal 
detachment was approaching the fovea.  Afterwards,  
the patient was followed for 6 years until the age of 
26 years to observe the diminution of the hemangioma 
(Fig. 3B-F).  She maintained a visual acuity of 1.2 in 
the left eye.
　 At the age of 22 years,  she began to have dysar-
thria,  numbness and weakness of the upper and lower 
extremities.  She had a mass with enhancement,  
accompanied by cystic components,  in the cerebellar 
tonsil and dorsal medulla oblongata (Fig. 1C,  D) and 
underwent extirpation by craniotomy and C1 laminec-
tomy to prove hemangioblastoma (Fig. 2C,  D).  At the 
age of 23 years,  the pancreatic tumors showed grad-
ual enlargement (Fig. 1E),  and whole-body 2-[18F]
ﬂuoro-2-deoxy-D-glucose positron emission tomogra-
phy fused with computed tomography (PET/CT) 
showed abnormal uptake sites in the pancreatic lesions 
(Fig. 1F) together with abnormal uptake in a regional 
lymph node.  She also showed multiple small nodular 
lesions in both lungs (Fig. 1G),  which were negative 
on the PET/CT.  She underwent endoscopic ultra-
sound-guided ﬁne-needle aspiration biopsy of the pan-
creatic tumor to reveal homogeneous round epithelioid 
cells,  positive for CD56 and synaptophysin,  sugges-
tive of neuroendocrine tumor.
　 At the age of 24 years,  she abruptly developed 
cold sweat,  nausea,  black stool,  and dimmed vision,  
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Fig. 1　 Bilateral adrenal tumors (arrows) with irregular internal structure on T1-weighted (A) and T2-weighted (B) magnetic resonance 
imaging at the age of 18 years; a cerebellar tonsil tumor with a cyst (arrows) on T1-weighted (C) and T2-weighted (D) magnetic resonance 
imaging at the age of 22 years; and multiple pancreatic tumors (arrows in E) on T1-weighted magnetic resonance imaging and abnormal 
uptake lesions (arrow in F,  the maximum standardized uptake value: SUVmax＝13.49) on whole-body 2-[18F]ﬂuoro-2-deoxy-D-glucose 
positron emission tomography fused with computed tomography (PET/CT) at the age of 23 years.  Multiple small nodular lesions in bilateral 
lungs on computed tomography,  metastatic from pancreatic neuroendocrine tumors,  observed at the age of 23 years (G),  remained sta-
tionary for one year after total pancreatectomy (H).
caused by intestinal bleeding from the pancreatic head.  
She decided to undergo total pancreatectomy and 
regional lymph nodes dissection to prove the presence 
of neuroend rocrine tumors (Fig. 2B).  The multiple 
pulmonary lesions remained stationary for 2 years 
(Fig. 1H),  and apancreatic status was controlled with 
the combination of insulin aspart and insulin glargine.
Discussion
　 Von Hippel-Lindau disease is classiﬁed into 2 
types: type I without pheochromocytoma and type II 
with pheochromocytoma [2].  Genetic analysis of the 
VHL gene showed that missense mutations,  i.e.,  amino 
acid-substituting changes,  were frequently found in 
type II while nonsense mutations,  i.e.,  protein-trun-
cating changes,  or large deletions were found mainly 
in type I [3,  4].  The present patient was revealed to 
have a heterozygous missense mutation,  712C to T 
(Arg167Trp) [3],  which is consistent with the geno-
typic features of von Hippel-Lindau disease type II.
　 Bilateral adrenal pheochromocytomas,  detected 
under the guidance of the initial symptoms of hyper-
tension and palpitation,  as in this patient,  are a key 
for diagnosing 2 familial diseases,  multiple endocrine 
neoplasia type 2 and von Hippel-Lindau disease [13].  
The present patient had a family history of pheochro-
mocytomas,  indicative of autosomal dominant inheri-
tance.  The detection of retinal hemangioma and the 
genetic analysis of the VHL gene conﬁrmed von 
Hippel-Lindau disease.  It should be noted that retinal 
hemangioma had been absent at the earlier age when 
the patient was ﬁrst seen by ophthalmologists for 
accommodative esotropia,  and that cerebellar heman-
gioblastoma was detected only later in the course of 
the follow-up.  After successful removal of the cere-
bellar hemangioblastoma,  she was carefully observed 
for any later development of spinal cord hemangio-
blastoma [14,  15].  Furthermore,  the total pancre-
atectomy in a case with neuroendocrine tumors,  as 
diagnosed in this patient,  is justiﬁed from the prog-
nostic point of view,  and metastatic lesions of neu-
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Fig. 2　 Hematoxylin-eosin staining of adrenal pheochromocytoma (A),  pancreatic neuroendocrine tumor (B),  and cerebellar hemangio-
blastoma (C).  Vimentin immunohistochemical staining of cerebellar hemangioblastoma (D).  Note that hemangioblasts are positive for 
vimentin.  Bar＝30µm.
139Radiation to Optic Disc HemangiomaApril 2011
A B
C D
E F
Fig. 3　 Optic disc hemangioma (arrows) in the left eye at the age of 19 years before external beam radiation (A),  3 months after 20 Gy 
radiation (B),  2 years later (C),  3 years later (D),  and 6 years later (E).  Horizontal retinal cross-sectional image (F) taken at the same time 
as the fundus photograph (E),  obtained by optical coherence tomography,  shows no subretinal or intraretinal ﬂuid in the macula.  Note that 
serous retinal detachment caused by hemangioma is reaching the fovea in A and B while the subretinal ﬂuid resolves with diminution of the 
hemangioma in C,  D,  and E.
roendocrine tumors,  even if present,  are known to be 
stable for many years [16,  17].  Therefore,  in this 
patient,  no additional treatment was planned,  and the 
metastatic lung lesions were observed during the fol-
low-up.
　 Hemangioma on the optic disc cannot be directly 
cryocauterized or coagulated by laser or treated with 
transpupillary thermotherapy.  Photodynamic therapy 
with verteporﬁn is successful in inducing degeneration 
of midperipheral large hemangiomas [11].  However,  
the use of photodynamic therapy to treat optic disc 
hemangioma would naturally induce optic disc capillary 
obstruction,  and thus,  would lead to optic disc atro-
phy and a loss of vision [11].  The eﬀect of intravit-
real injection of anti-VEGF antibody drugs on retinal 
hemangioma has been reported recently,  but the injec-
tion is expected to be repeated several times to con-
trol the activity of the tumor [12],  based on the 
experience in age-related macular degeneration in 
which repeat injections are mandatory to control 
choroidal neovascularization,  as described in a stan-
dard regimen.  Most recently,  the combination of 
photodynamic therapy with intravitreal injections of 
anti-VEGF drugs has been described as eﬀective to 
control serous retinal detachment caused by optic disc 
hemangioma in a case report [18].  Even in this com-
bined therapy,  repeat sessions of both photodynamic 
therapy and intravitreal anti-VEGF drug injections 
were required over a period of 5 months.
　 A decade ago,  when intravitreal injection of anti-
VEGF antibody drugs was not available,  external 
beam radiation at a low dose (20 Gy) was chosen as an 
initial main treatment since the leakage from the optic 
disc hemangioma reached the macula to reduce the 
vision in the present patient.  The external beam 
radiation was shown to be eﬀective,  though at slow 
speed,  in controlling the optic disc hemangioma with-
out causing any adverse eﬀects over a follow-up period 
as long as 6 years.  Furthermore,  from the standpoint 
of requiring no additional treatment,  external beam 
radiotherapy appears to be superior to photodynamic 
therapy and intravitreal anti-VEGF drug injections,  
both of which require repeat treatments [11,  12,  
18].  In comparison with photodynamic therapy and 
intravitreal anti-VEGF drug injections,  the need for 
less frequent ophthalmological follow-up visits,  
required after radiotherapy,  is also a merit of the 
external beam radiation,  as in this patient who had 
systemic manifestations and underwent multiple sur-
geries.
　 In conclusion,  low-dose external beam radiation 
was eﬀective in reducing the leakage and diminishing 
the size of optic disc hemangioma to preserve the 
central vision over a long follow-up term.  External 
beam radiation is recommended as an initial treatment 
option for optic disc hemangioma,  even in the current 
situation where other modalities of treatment are 
available.
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